The discovery and development process for Antibody Drug Conjugates (ADCs), or immunoconjugates, is complex and poses significant challenges. Genedata Biologics® supports the full ADC discovery process from antibody screening and engineering, to antibody expression, purification, drug conjugation, and reporting of ADC-specific analytics (e.g., DAR, drug distribution, homogeneity).
ADC Design, Engineering & Testing
Genedata Biologics enables the registration and tracking of large panels of ADC candidates and manages all linker and payload information (e.g., cytotoxic small molecules). By incorporating results from analytics and functional assays in one integrated platform, Genedata Biologics substantially increases throughput and efficiency in ADC discovery.
Design, Track, Test, & Assess mAbs, Bispecifics, and ADCs
Merck went from a fragmented research landscape using different tools and technologies to generate and store data to integrating Genedata Biologics at the center of operations to increase efficiency and accelerate discovery operations.
Antibody Drug Conjugate (ADC) Therapies for Cancer Treatment
"All our novel ADCs are registered in Genedata, and the platform’s end-to-end capabilities have transformed our research operations, enabling us to systematically advance our next-generation ADC candidates to the clinic.”
Automating the Discovery of Novel Biological Therapeutics
Genedata Biologics integrates and automates complex biologics research processes resulting in a significant reduction in discovery timelines. By providing structured, high-quality, and comparable data, Genedata Biologics enables data-driven decisions to select the most promising lead candidates.
Scalable Backbone System Supports ADC Discovery
"Thanks to its flexible architecture, Genedata Biologics can truly support our entire discovery process—right through from the immunization of transgenic mice, to lead selection, molecular modification and final candidate assessments.”